In the news release, Veloxis Pharmaceuticals to Present Results from a Patient Subgroup Analysis of Once-Daily LCP-Tacro(TM) in Stable African-American Kidney Transplant Patients at American Transplant

HORSHOLM, Denmark, May 31, 2012 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that a subgroup analysis of African-American stable kidney transplant patients enrolled

HORSHOLM, Denmark, May 23, 2012 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that it contemplates restructuring the company's operations in order to fully focus its

HORSHOLM, Denmark, March 29, 2012 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that enrolment has been completed in its pivotal LCP-Tacro Phase III study in de novo

ABBOTT PARK, Ill., Feb.